Načítá se...
3-year Treatment of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate for Chronic HBV Infection in China
BACKGROUND AND AIMS: Tenofovir alafenamide (TAF) has similar efficacy to tenofovir disoproxil fumarate (TDF) but with improved renal and bone safety in chronic hepatitis B patients studied outside of China. We report 3-year results from two phase 3 studies with TAF in China (Clinicaltrials.gov: NCT0...
Uloženo v:
Vydáno v: | J Clin Transl Hepatol |
---|---|
Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , , |
Médium: | Artigo |
Jazyk: | Inglês |
Vydáno: |
XIA & HE Publishing Inc.
2021
|
Témata: | |
On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8237145/ https://ncbi.nlm.nih.gov/pubmed/34221918 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14218/JCTH.2020.00145 |
Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|